Project Grant R61AG094602
Award Date 8/1/25
Completion Date 7/31/27
Dollars Obligated $2.1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) will provide $1,257,163.00 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) for treating Alzheimer's disease and associated health conditions in individuals with Down syndrome. The project aims to first measure FSH levels across the lifespan in mouse models of...
- This $2,220,145 federal Project Grant award, funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), aims to optimize and develop novel cell-type-selective adeno-associated virus (AAV) vector technologies to study disease-relevant cell types and neural circuits in mouse models of aging and Alzheimer's disease. The key products and services to be delivered include: Developing enhanced AAV vectors that can genetically target and manipulate specific brain cell...
- The U.S. National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $2,329,970 Project Grant to the University of Florida to conduct research on "Evaluation of the Neuroimmune Mechanisms Influencing Therapeutic Targeting Potential of the LH/CG Receptor in the Menopausal and AD Brain". This 4-year project, running from September 1, 2025 to August 31, 2029, seeks to investigate the potential immune-regulating role of the LH/CG receptor...
- The National Institute on Aging (NIA) awarded a $1,459,072 project grant to the J. David Gladstone Institutes under the Aging Research Federal Grant Program (CFDA 93.866) to monitor and manipulate inhibitory interneuron cell populations in mouse models of Alzheimer's disease. The 2-year project aims to use dual cell-type-specific enhancer-associated adeno-associated viruses (enhancer-AAVs) to independently monitor and control parvalbumin (PVALB) and somatostatin (SST) inhibitory interneurons...
- This $721,089.02 federal Project Grant award from the National Institute on Aging (part of the National Institutes of Health) under the Aging Research program (CFDA 93.866) will support research to delineate how epigenetic regulation of the ACVR1C gene contributes to age- and Alzheimer's disease-related memory impairments in females and males. The goal is to determine if ACVR1C functions as a self-regulating mechanism underlying these cognitive declines, and if overriding ACVR1C impairment can...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,257,163 to the Icahn School of Medicine at Mount Sinai to develop a humanized monoclonal antibody targeting follicle-stimulating hormone (FSH) as a potential treatment for Alzheimer's disease in individuals with Down syndrome. The 5-year project, beginning on Jul 1, 2025, will first measure FSH levels across the lifespan in mouse models of Down syndrome...
- This federal Project Grant award of $2,316,710 from the National Institute on Aging (CFDA 93.866 Aging Research) aims to develop magnetogenetic techniques for manipulating the activity of specific brain cell types implicated in the onset and progression of Alzheimer's disease (AD). The research will focus on using a magnetogenetic tool called FERIC (Ferritin Iron Redistribution to Ion Channels) in combination with enhancer AAV vectors to non-invasively control the activity of AD-vulnerable...
- The National Institutes of Health National Institute on Aging awarded $3,024,000 under the Aging Research federal grant program (CFDA 93.866) to the Massachusetts General Hospital on September 30, 2022 for a project concluding on August 31, 2025. The award will support research into discovering sex-linked genes on the inactive X chromosome that may influence female vulnerability to Alzheimer's disease pathology. The awardee will employ genomic, transcriptomic, and epigenetic analysis to...
- This Project Grant award, with a total funding amount of $878,190.00, was provided by the National Institute on Aging (part of the U.S. Department of Health and Human Services) under the Aging Research federal grant program (CFDA 93.866). The grant is supporting research by the Scripps Research Institute in California to investigate a "druggable mito-nuclear feedback mechanism" that can preserve mitochondrial and synaptic function in aging and age-related dementias like Alzheimer's...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), is focused on investigating the association between the Alzheimer's disease (AD) risk gene APOE4 and the menopause-related hormone follicle-stimulating hormone (FSH) in the initiation and progression of AD, particularly in women. The $564,530 award to Emory University will support research to explore how APOE4 may facilitate AD pathology in women by interacting with FSH-induced...